Neurocrine Biosciences, Inc. (NBIX)
164.63
+4.87
(+3.05%)
USD |
NASDAQ |
Nov 06, 16:00
164.65
+0.02
(+0.01%)
After-Hours: 20:00
Neurocrine Biosciences Research and Development Expense (Quarterly) : 351.80M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 351.80M |
| June 30, 2026 | 326.70M |
| March 31, 2026 | 296.20M |
| December 31, 2025 | 258.20M |
| September 30, 2025 | 250.00M |
| June 30, 2025 | 244.30M |
| March 31, 2025 | 263.20M |
| December 31, 2024 | 179.40M |
| September 30, 2024 | 189.40M |
| June 30, 2024 | 184.70M |
| March 31, 2024 | 154.10M |
| December 31, 2023 | 132.60M |
| September 30, 2023 | 137.60M |
| June 30, 2023 | 141.60M |
| March 31, 2023 | 135.40M |
| December 31, 2022 | 114.10M |
| September 30, 2022 | 103.70M |
| June 30, 2022 | 132.00M |
| March 31, 2022 | 98.90M |
| December 31, 2021 | 84.40M |
| September 30, 2021 | 89.90M |
| June 30, 2021 | 72.20M |
| March 31, 2021 | 70.70M |
| December 31, 2020 | 64.50M |
| September 30, 2020 | 66.90M |
| Date | Value |
|---|---|
| June 30, 2020 | 78.80M |
| March 31, 2020 | 56.20M |
| December 31, 2019 | 53.21M |
| September 30, 2019 | 45.28M |
| June 30, 2019 | 61.69M |
| March 31, 2019 | 36.09M |
| December 31, 2018 | 39.11M |
| September 30, 2018 | 35.48M |
| June 30, 2018 | 36.99M |
| March 31, 2018 | 48.95M |
| December 31, 2017 | 25.61M |
| September 30, 2017 | 22.46M |
| June 30, 2017 | 21.87M |
| March 31, 2017 | 51.88M |
| December 31, 2016 | 22.58M |
| September 30, 2016 | 20.94M |
| June 30, 2016 | 26.86M |
| March 31, 2016 | 23.90M |
| December 31, 2015 | 21.81M |
| September 30, 2015 | 24.39M |
| June 30, 2015 | 18.72M |
| March 31, 2015 | 16.58M |
| December 31, 2014 | 15.50M |
| September 30, 2014 | 12.19M |
| June 30, 2014 | 10.16M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Amgen, Inc. | 2.111B |
| Halozyme Therapeutics, Inc. | 27.78M |
| BioCryst Pharmaceuticals, Inc. | 57.97M |
| Iovance Biotherapeutics, Inc. | 49.34M |
| Precigen, Inc. | 6.313M |